ENGLEWOOD, Colo., Dec. 27 /PRNewswire/ -- The "Clinical and Economical Considerations For IV Push Drug Delivery" technical paper -- authored by Industry Expert Richard Rosenfeld, RPh, MBA, for Baxa Corporation -- is now accessible at http://expert411.com/_wsn/page16.html for media and professional reference. The paper is an overview of the historical background for IV push and a model for implementation of a successful program.
IV push of cephalosporin antibiotics and other drugs is an alternative method of administration that can be safe, efficacious and cost effective. This paper concentrates on IV push of cefazolin as a case study, since it is a high-use cephalosporin with physical and chemical properties similar to other drugs that can be administered by the IV push method.
Rosenfeld has personally implemented the use of IV push antibiotics within two hospital systems. During the first year that this IV push program was in place, more than 50,000 doses of cefazolin were administered by the IV push method with no occurrences of phlebitis or adverse drug events directly associated with the change in the administration method of this drug. The paper discusses the economical advantages of moving to IV push, as well as the resulting nurse satisfaction and patient benefits seen through the resulting research followup.
Executive Director of Pharmacy Management for the Scripps Health Hospital System in San Diego, CA, Rosenfeld has responsibility for all system pharmacy services through his position with Cardinal Technology and Services. Prior to joining the Scripps Health team, he served as a consultant at Sharp Healthcare, a five-hospital IDN in San Diego, California, where the IV push method of administration for cephalosporins was implemented.
Rosenfeld earned a BS in Pharmacy from Ferris State University and a BA in Chemistry from San Diego State University. He holds an MBA from California State University, San Marcos.
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative,
solution-based technologies for fluid handling and delivery. Its systems
and devices promote the safe and efficient preparation, handling,
packaging, and administration of fluid medications. Key products include
the PadLock(R) Set Saver, Rapid-Fill(TM) Automated Syringe Fillers,
Exacta-Med(R) Oral Dispensers, MicroFuse(R) Syringe Infusers, Repeater(TM)
Pharmacy Pumps, and Exacta-Mix(TM) and MicroMacro(TM) Multi-Source
Automated Compounders; used worldwide in hospitals and healthcare
facilities. Privately held, Baxa Corporation has subsidiaries and sales
offices in Canada and the United Kingdom; direct representation in Austria,
Belgium, Finland, France, Germany, Luxembourg, The Netherlands and
Switzerland; and distribution partners worldwide. Further information is
available at http://www.baxa.com.
Marian Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Maggie Chamberlin Holben, APR, Absolutely Public Relations
|SOURCE Baxa Corporation|
Copyright©2007 PR Newswire.
All rights reserved